
BTSG Stock Forecast & Price Target
BTSG Analyst Ratings
Bulls say
BrightSpring Health is favored because its integrated pharmacy-plus-provider model serves clinically complex, sticky patients, with about six chronic conditions and nine medications on average, while its large $1T+ TAM and rising home-based care demand support durable growth. Its pharmacy platform has meaningful upside from limited distribution drugs, oncology and specialty launches, and the company has already won 12 LDDs YTD with about 20 expected in 2026, while EBITDA per Rx grew 44% y/y in 2Q:26. Management’s disciplined capital allocation, leverage target of 2.5x debt/EBITDA or below, expected 2026 CFFO of $600M+ and FCF above $500M, plus AI-driven cost savings and accretive tuck-in M&A, strengthen the earnings outlook.
Bears say
BrightSpring Health is exposed to a difficult operating backdrop where its pharmacy and provider businesses depend heavily on Medicare and Medicaid reimbursement, while state and federal payment changes can pressure rates, margins, and demand. The company also faces meaningful execution risk from labor recruitment and retention, payor scrutiny, drug-related supply and pricing changes, and integration challenges after the recent Amedisys/LHC asset acquisition, all of which can disrupt profitability. Although management expects the IRA EBITDA drag to fall by 50% in 2027 from a $15 million headwind in 2026, the business still carries competitive and regulatory risks in a highly contested specialty and home-based care market.
This aggregate rating is based on analysts' research of BrightSpring Health Services Inc and is not a guaranteed prediction by Public.com or investment advice.
BTSG Analyst Forecast & Price Prediction
Start investing in BTSG
Order type
Buy in
Order amount
Est. shares
0 shares